Evidence map›Paper›PMID 39206012›Full record

ArticleFrontiers in public health2024

Acceptance of a third COVID-19 vaccine dose, vaccine interchangeability, and clinical trial enrolment among parents of children 12-17 years in Lima, Perú.

Carlos R Celis, Lucie Ecker, Giancarlo Alvarado-Gamarra, Katherine Alcalá-Marcos, Noé Atamari-Anahui, Maria Pia Balmaceda, Kevin Florian, Rodrigo Paredes de la Fuente, Leigh M Howard, Carlos G Grijalva and 1 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Carlos R CelisInstituto de Investigación Nutricional, Lima, Peru.
Lucie EckerInstituto de Investigación Nutricional, Lima, Peru.
Giancarlo Alvarado-GamarraInstituto de Investigación Nutricional, Lima, Peru.
Katherine Alcalá-MarcosInstituto de Investigación Nutricional, Lima, Peru.
Noé Atamari-AnahuiUnidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Maria Pia BalmacedaNora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT, United States.
Kevin FlorianInstituto de Investigación Nutricional, Lima, Peru.
Rodrigo Paredes de la FuenteDepartment of Medicine, Mount Sinai West/Morningside Hospital, Ichan School of Medicine at Mount Sinai, New York, NY, United States.
Leigh M HowardDepartment of Pediatrics, School of Medicine, Vanderbilt University, Nashville, TN, United States.
Carlos G GrijalvaDepartment of Health Policy, Vanderbilt University Medical Center, Nashville, TN, United States.
Claudio F LanataInstituto de Investigación Nutricional, Lima, Peru.

Funding

Peru Vanderbilt – PREvention through VacciNation Training (PREVENT) programD43TW012468 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CARLOS G GRIJALVA, Claudio Franco Lanata · 2023 to 2026
$992k
6 · The paper itself

Abstract

Objectives: To characterize factors associated with parental willingness for their children participation in a COVID-19 vaccine trial, use of different COVID-19 vaccines and acceptance of a third vaccine dose. Methods: Parents of children aged 12-17 years in Lima, Perú were asked to complete an online questionnaire via social networks, from November 9, 2021, to April 23, 2022. We calculated crude and adjusted prevalence ratios with 95% confidence intervals to compare factors with the mentioned outcomes. Results: From 523 parents responding, 374 completed the survey. 90.4% would give their children a third vaccine dose, 36.6% would allow their children participation in a COVID-19 vaccine clinical trial, and 33.2% would accept different vaccine brands between doses. Parental belief that COVID-19 vaccine studies met quality standards was associated with acceptance of a third booster dose (adjusted PR 3.25; 95% CI1.57-6.74; Conclusion: Most parents would accept a third vaccine booster dose, approximately a third would participate in COVID-19 vaccine trials. Believing COVID-19 vaccines studies fulfilled quality standards was associated with the study outcomes. It is necessary to inform about the rigorous processes for the development of COVID-19 vaccines to generate confidence in parents to accept these vaccine-related outcomes.

Indexed as

COVID-19COVID-19 VaccinesParentsAdolescentAdultChildClinical Trials as TopicFemaleHumansImmunization, SecondaryMalePatient Acceptance of Health CareSARS-CoV-2Surveys and QuestionnairesVaccination HesitancyCOVID-19 VaccinesCOVID-19 vaccinesparentspatient acceptance of health carepediatricsvaccination

Identifiers

PMID39206012
PMCPMC11349562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.